Kōichi Goto

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 912 citations

Medicine, Oncology, Pharmacology +14

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan et al. · New England Journal of Medicine · 2020 · 836 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Shogo Kumagai, Yosuke Togashi, Takahiro Kamada et al. · Nature Immunology · 2020 · 812 citations

Life Sciences, Immunology, Oncology +17

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto, Terufumi Kato, Makoto Nishio et al. · The Lancet Oncology · 2014 · 749 citations

Medicine, Oncology, Pharmacology +14